Group 1 - The company Chengyi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and CICC as joint sponsors [1] - Chengyi Biotechnology is a global biotechnology company focused on developing oral small molecule drugs to address significant medical needs in cardiovascular metabolic diseases and inflammatory diseases [1] - The company utilizes its proprietary TRANDD platform, with a product pipeline that includes oral small molecule GLP-1 receptor agonist ECC5004, which is expected to be the best-in-class and the second oral small molecule GLP-1RA to be launched globally [1] Group 2 - The product pipeline also features an oral liver-targeted thyroid hormone receptor β full agonist ECC4703, which is anticipated to be the best-in-class for MASH treatment and the second to market, or a first-in-class liver-targeted selective THR-β full agonist for weight management [1] - Additionally, the pipeline includes an amino-urea sensitive amine oxidase inhibitor ECC0509, which can be used in combination with GLP-1 receptor agonists [1]
诚益生物递表港交所 致力于研发口服小分子药物
Zheng Quan Shi Bao Wang·2025-10-09 00:15